Vaccines and Infectious Diseases · global
Needle-free “naked mRNA” vaccines with two adjuvants protect mice against COVID-19 and influenza
Can mRNA still provide sufficient protection without lipid encapsulation? A mouse study combined high-pressure liquid jets with two adjuvants, reducing infectious virus in the lungs to below the detection limit after viral challenge. Dose and safety validation remain necessary before human use.
For mRNA vaccines to work, they must deliver genetic instructions into cells and help the immune system remember the antigens those instructions produce. Researchers in Japan and the United States explored another delivery route: instead of encapsulating mRNA in lipid nanoparticles, they delivered it into the skin using high-pressure liquid jets and combined it with two immune adjuvants. In separate mouse experiments targeting the coronavirus and influenza virus, this needle-free strategy showed protective effects, but it has not yet entered human trials.
The study was published on October 20 in the *Journal of Clinical Investigation*. The team used “naked mRNA” modified with N1-methylpseudouridine. Here, “naked” means that the mRNA is not encapsulated in a carrier, rather than that it lacks molecular modifications. The skin is rich in immune cells, but previous delivery of mRNA by liquid jet injection elicited only limited immune responses. Strengthening those responses was the central focus of the study.
Simply choosing any existing adjuvant was not enough. The researchers screened several adjuvants with a history of clinical use and found that many offered limited benefit when used alone, or even suppressed some immune responses. Combining aluminum phosphate with CpG oligonucleotides, however, enhanced both antibody responses and cellular immunity. Mechanistic experiments also indicated that type I interferon and interleukin-6 signaling were involved, suggesting that the delivery method and immune stimulation need to be optimized together.
According to Rutgers University’s account and a report from the same source published by Medical Xpress, mice received three doses of the vaccine containing both adjuvants and were then challenged separately with SARS-CoV-2 or A/California/7/2009 H1N1 influenza virus. Infectious virus in lung samples was below the detection limit in both experiments. In the coronavirus experiment, lung viral RNA was approximately one twenty-fourth of that in the group given the vaccine without adjuvants. However, undetectable infectious virus does not mean that the body is entirely free of virus, nor does it directly establish that transmission can be blocked.
The influenza experiment had another limitation in interpretation: mice in both vaccine groups, with and without adjuvants, survived. The study therefore supports improved viral control with the two adjuvants, but does not demonstrate an additional survival benefit beyond the vaccine’s existing effect. This also reminds readers that antibodies, viral load, and survival rates each answer different questions and cannot substitute for one another.
In separate comparative experiments, this naked mRNA formulation elicited less local and systemic inflammation than the laboratory lipid nanoparticle formulation used in the study. This provides a lead for further development, but the limited comparator and experimental conditions are insufficient to claim that it is safer than marketed mRNA vaccines or offers better clinical protection.
Next, the team still needs to confirm the effects in larger animals and identify an appropriate dose before advancing to human trials. Even though the jet injection device and adjuvant components each have a history of human use, this new combination still requires full validation. The advance at this stage is concrete evidence of protection in mice from an mRNA vaccine that does not rely on lipid encapsulation.